ORGANOIDSCIENCES LTD.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureORGANOIDSCIENCES LTD. was founded in October 2018 and listed on the KOSDAQ market in May 2025 as an organoid-based biotech company. Its core business spans the intestinal organoid therapeutic ATORM-C built on the ATORM regenerative-therapeutics platform, the new-material evaluation solution ODISEI, and the research reagent brand organoEZ. The tumor organoid evaluation solution ODISEI-ONC was commercialized in 2020, ODISEI uses more than 20 types of organ-specific organoids, and the company has also expanded into immuno-oncology precision medicine and cell/tissue-engineering CDMO services.
Products & technology
- ATORM-CSingle local-administration therapeutic derived from adult stem cell-based intestinal organoids for refractory intestinal ulcers (IBD, Behcet's enteritis, radiation proctitis, stercoral ulcer)
- ODISEIOrganoid-based new-material evaluation solution predicting human-body effects of new materials for drugs, food, and cosmetics, using more than 20 types of organ-specific organoids (tumor, virus, intestine, skin, etc.)
- organoEZCustomized organoid research reagent product line leveraging the company's culture know-how
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2026 (Phase 1 1)
- Phase 1ATORM-C2026-03-13
2 trial sites
R&D and key agreements
Source: DART corporate disclosureATORM-C · 난치성 장궤양(염증성 장질환(IBD), 베체트 장염, 방사선 직장염, 숙변성 궤양 등) · 첨단재생의료 임상연구(2022년 보건복지부 승인, 진행중) · In December 2025, filed an IND application with the MFDS for a Phase 1 clinical trial in patients with Crohn's disease accompanied by colonic ulcers
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIOAI-SearchBot4
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition